Ascendis Pharma A (ASND) EBIAT: 2014-2025
Historic EBIAT for Ascendis Pharma A (ASND) over the last 12 years, with Sep 2025 value amounting to -$71.3 million.
- Ascendis Pharma A's EBIAT rose 34.55% to -$71.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$255.9 million, marking a year-over-year increase of 44.67%. This contributed to the annual value of -$409.2 million for FY2024, which is 21.00% up from last year.
- According to the latest figures from Q3 2025, Ascendis Pharma A's EBIAT is -$71.3 million, which was down 62.11% from -$44.0 million recorded in Q2 2025.
- Ascendis Pharma A's 5-year EBIAT high stood at -$41.1 million for Q4 2024, and its period low was -$211.6 million during Q4 2022.
- In the last 3 years, Ascendis Pharma A's EBIAT had a median value of -$108.9 million in 2024 and averaged -$104.2 million.
- As far as peak fluctuations go, Ascendis Pharma A's EBIAT slumped by 85.96% in 2022, and later spiked by 62.66% in 2025.
- Quarterly analysis of 5 years shows Ascendis Pharma A's EBIAT stood at -$121.3 million in 2021, then slumped by 74.41% to -$211.6 million in 2022, then soared by 55.83% to -$93.5 million in 2023, then surged by 56.02% to -$41.1 million in 2024, then surged by 34.55% to -$71.3 million in 2025.
- Its last three reported values are -$71.3 million in Q3 2025, -$44.0 million for Q2 2025, and -$99.5 million during Q1 2025.